213 related articles for article (PubMed ID: 19607914)
1. The emerging role of TGF-beta superfamily coreceptors in cancer.
Bernabeu C; Lopez-Novoa JM; Quintanilla M
Biochim Biophys Acta; 2009 Oct; 1792(10):954-73. PubMed ID: 19607914
[TBL] [Abstract][Full Text] [Related]
2. Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFbeta receptor independent manner.
Parker WL; Goldring MB; Philip A
J Bone Miner Res; 2003 Feb; 18(2):289-302. PubMed ID: 12568406
[TBL] [Abstract][Full Text] [Related]
3. Identification of endoglin in rat hepatic stellate cells: new insights into transforming growth factor beta receptor signaling.
Meurer SK; Tihaa L; Lahme B; Gressner AM; Weiskirchen R
J Biol Chem; 2005 Jan; 280(4):3078-87. PubMed ID: 15537649
[TBL] [Abstract][Full Text] [Related]
4. Structural biology of betaglycan and endoglin, membrane-bound co-receptors of the TGF-beta family.
Kim SK; Henen MA; Hinck AP
Exp Biol Med (Maywood); 2019 Dec; 244(17):1547-1558. PubMed ID: 31601110
[TBL] [Abstract][Full Text] [Related]
5. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors.
Wong SH; Hamel L; Chevalier S; Philip A
Eur J Biochem; 2000 Sep; 267(17):5550-60. PubMed ID: 10951214
[TBL] [Abstract][Full Text] [Related]
6. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway.
Santander C; Brandan E
Cell Signal; 2006 Sep; 18(9):1482-91. PubMed ID: 16413747
[TBL] [Abstract][Full Text] [Related]
7. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan.
Letamendía A; Lastres P; Botella LM; Raab U; Langa C; Velasco B; Attisano L; Bernabeu C
J Biol Chem; 1998 Dec; 273(49):33011-9. PubMed ID: 9830054
[TBL] [Abstract][Full Text] [Related]
8. Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells.
Zhang H; Shaw AR; Mak A; Letarte M
J Immunol; 1996 Jan; 156(2):564-73. PubMed ID: 8543807
[TBL] [Abstract][Full Text] [Related]
9. TGF-β and its coreceptors in cancerogenesis: an overview.
Todorović-Raković N; Milovanović J; Nikolić-Vukosavljević D
Biomark Med; 2011 Dec; 5(6):855-63. PubMed ID: 22103622
[TBL] [Abstract][Full Text] [Related]
10. Roles for the type III TGF-beta receptor in human cancer.
Gatza CE; Oh SY; Blobe GC
Cell Signal; 2010 Aug; 22(8):1163-74. PubMed ID: 20153821
[TBL] [Abstract][Full Text] [Related]
11. Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.
Mendoza V; Vilchis-Landeros MM; Mendoza-Hernández G; Huang T; Villarreal MM; Hinck AP; López-Casillas F; Montiel JL
Biochemistry; 2009 Dec; 48(49):11755-65. PubMed ID: 19842711
[TBL] [Abstract][Full Text] [Related]
12. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation.
Droguett R; Cabello-Verrugio C; Riquelme C; Brandan E
Matrix Biol; 2006 Aug; 25(6):332-41. PubMed ID: 16766169
[TBL] [Abstract][Full Text] [Related]
13. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.
López-Casillas F; Payne HM; Andres JL; Massagué J
J Cell Biol; 1994 Feb; 124(4):557-68. PubMed ID: 8106553
[TBL] [Abstract][Full Text] [Related]
14. Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer.
Choi AS; Jenkins-Lane LM; Barton W; Kumari A; Lancaster C; Raulerson C; Ji H; Altomare D; Starr MD; Whitaker R; Phaeton R; Arend R; Shtutman M; Nixon AB; Hempel N; Lee NY; Mythreye K
Cell Commun Signal; 2024 Feb; 22(1):128. PubMed ID: 38360757
[TBL] [Abstract][Full Text] [Related]
15. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
[TBL] [Abstract][Full Text] [Related]
16. Betaglycan: a multifunctional accessory.
Bilandzic M; Stenvers KL
Mol Cell Endocrinol; 2011 Jun; 339(1-2):180-9. PubMed ID: 21550381
[TBL] [Abstract][Full Text] [Related]
17. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
[TBL] [Abstract][Full Text] [Related]
18. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.
Vilchis-Landeros MM; Montiel JL; Mendoza V; Mendoza-Hernández G; López-Casillas F
Biochem J; 2001 Apr; 355(Pt 1):215-22. PubMed ID: 11256966
[TBL] [Abstract][Full Text] [Related]
19. Structure of betaglycan zona pellucida (ZP)-C domain provides insights into ZP-mediated protein polymerization and TGF-beta binding.
Lin SJ; Hu Y; Zhu J; Woodruff TK; Jardetzky TS
Proc Natl Acad Sci U S A; 2011 Mar; 108(13):5232-6. PubMed ID: 21402931
[TBL] [Abstract][Full Text] [Related]
20. Betaglycan has multiple binding sites for transforming growth factor-beta 1.
Kaname S; Ruoslahti E
Biochem J; 1996 May; 315 ( Pt 3)(Pt 3):815-20. PubMed ID: 8645162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
